Therapeutic Vision, Inc. is focused on the development of pharmaceuticals primarily for the companion animal market. The company is developing age-related and diabetic therapies for the ophthalmic and dental issues. The firm has two products on the market focused on cataracts. Kinostat is a topical aldose reductase inhibitor that is anticipated to receive FDA approval in the Winter 2016 / Spring 2017. FDA toxicological approval was received in Spring, 2015 and the multi-centered clinical trial was completed in January, 2016. In addition, Therapeutic Vision offers contract toxicological research services to evaluate the effects of drugs on lens opacity/cataract formation
